



# **ADAPT SMART NEWDIGS Presentation**

20 - 22 Mar 2018

Poll results

## Table of contents

- Which team do you expect to win Group A in the 2018 World Cup?
- What is your primary affiliation?
- Which stakeholder benefits the LEAST from MAPPs?
- Which stakeholder benefits the MOST from MAPPs?
- On a scale of 1 (worst) to 6 (best): How well do you think Budapest Bio's MAR-18 product meets the MAPPs engagement criteria?
- From the perspective of  $\beta$ -thalassemia PATIENTS: which access mechanisms are likely to cause the most CONCERN?
- From the perspective of PAYERS: which access mechanisms are likely to be the most ATTRACTIVE?
- From the perspective of Budapest Bio (and other DEVELOPERS): which access mechanisms are likely to cause the most CONCERN?
- Given TODAY'S health care delivery context, who WILL bear the cost of generating real world evidence?
- Who SHOULD bear the cost of generating real world evidence?
- Which stakeholders do you believe will need to

## Table of contents

- collaborate the most in implementing MAPPs? (choose 2)
- Which stakeholders do you believe are likely to find collaboration most DIFFICULT? (choose 2)
- MAPPs use is likely in the next 24 months.

# Which team do you expect to win Group A in the 2018 World Cup?

037

Egypt

3 %

Russia

30 %

Uruguay

62 %

Saudi Arabia

5 %

# What is your primary affiliation? (1/2)

040

Academia



Healthcare Professional



HTA



Industry



Patient



Payer



# What is your primary affiliation? (2/2)

0 4 0

Regulator



Other



# Which stakeholder benefits the LEAST from MAPPs?

(1/2)

0 4 3

Academia



Healthcare Professional



HTA



Industry



Patient



# Which stakeholder benefits the LEAST from MAPPs?

(2/2)

043

Payer



Regulator



Other





# Which stakeholder benefits the MOST from MAPPs?

043

(1/2)

Healthcare Professional

2 %

HTA

0 %

Industry

19 %

Patient

74 %

Payer

2 %

# Which stakeholder benefits the MOST from MAPPs?

0 4 3

(2/2)

Regulator

2 %


Other

0 %

**On a scale of 1 (worst) to 6 (best): How well do you think Budapest Bio's MAR-18 product meets the MAPPs engagement criteria?**

0 4 3


Score: 4.5





0 4 4

**From the perspective of  $\beta$ -thalassemia PATIENTS: which access mechanisms are likely to cause the most CONCERN?**  
(1/2)





0 4 4

**From the perspective of  $\beta$ -thalassemia PATIENTS: which access mechanisms are likely to cause the most CONCERN?**  
(2/2)

Indication-based pricing



Withdrawal



Developer pays medical costs for failures





0 4 5

# From the perspective of PAYERS: which access mechanisms are likely to be the most ATTRACTIVE?

(1/2)

Eligibility authorization



Centers of excellence



Performance rebate



Conditional reimbursement



Coverage with evidence development





0 4 5

**From the perspective of PAYERS: which access mechanisms are likely to be the most ATTRACTIVE?**

(2/2)

Indication-based pricing



Withdrawal



Developer pays medical costs for failures



# From the perspective of Budapest Bio (and other DEVELOPERS): which access mechanisms are likely to cause the most CONCERN?

0 4 4

(1/2)

Eligibility authorization



Centers of excellence



Performance rebate



Conditional reimbursement



Coverage with evidence development





**From the perspective of Budapest Bio (and other DEVELOPERS): which access mechanisms are likely to cause the most CONCERN?**

0 4 4

(2/2)

Indication-based pricing



Withdrawal



Developer pays medical costs for failures





038

# Given TODAY'S health care delivery context, who WILL bear the cost of generating real world evidence? (1/2)

Academia (non-HCPs)



Healthcare Professionals (HCPs)



HTAs



Industry



Patients/Patient Groups



**Given TODAY'S health care delivery context, who WILL bear the cost of generating real world evidence?**

(2/2)

Payers



Regulators



# Who **SHOULD** bear the cost of generating real world evidence?

039

(1/2)

Academia (non-HCPs)



Healthcare Professionals (HCPs)



HTAs



Industry



Patients/Patient Groups



# Who **SHOULD** bear the cost of generating real world evidence?

0 3 9

(2/2)

Payers



Regulators





040

# Which stakeholders do you believe will need to collaborate the most in implementing MAPPs? (choose 2)

(1/2)

Academia



Healthcare Professional



HTA



Industry



Patient



**Which stakeholders do you believe will need to collaborate the most in implementing MAPPs? (choose 2)**  
(2/2)

0 4 0

Payer



Regulator



Other





040

# Which stakeholders do you believe are likely to find collaboration most **DIFFICULT**? (choose 2)

(1/2)

Academia



Healthcare Professional



HTA



Industry



Patient







**Which stakeholders do you believe are likely to find collaboration most DIFFICULT? (choose 2)**  
(2/2)

0 4 0

Payer



Regulator



Other



# MAPPs use is likely in the next 24 months.

042

Agree



Disagree

